Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

$5.70
-0.13 (-2.23%)
(As of 05:27 PM ET)
Today's Range
$5.57
$6.10
50-Day Range
$3.86
$5.83
52-Week Range
$3.67
$29.88
Volume
941,953 shs
Average Volume
1.08 million shs
Market Capitalization
$564.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Acelyrin MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
123.0% Upside
$12.80 Price Target
Short Interest
Bearish
11.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Acelyrin in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.33) to ($4.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

Medical Sector

542nd out of 901 stocks

Pharmaceutical Preparations Industry

252nd out of 427 stocks

SLRN stock logo

About Acelyrin Stock (NASDAQ:SLRN)

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

SLRN Stock Price History

SLRN Stock News Headlines

Acelyrin (NASDAQ:SLRN) Upgraded at Wells Fargo & Company
Acelyrin (NASDAQ:SLRN) Trading Up 0.7%
Don’t say I didn’t warn you…
All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.
Acelyrin, Inc. (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
Don’t say I didn’t warn you…
All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.
Acelyrin Founder Steps Down as CEO
ACELYRIN, INC. Announces Leadership Transition
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
See More Headlines
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/12/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+119.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.74 per share

Miscellaneous

Free Float
85,559,000
Market Cap
$577.34 million
Optionable
Optionable
Beta
2.56
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Ms. Melanie Gloria B.S.N. (Age 46)
    Chief Operating Officer
    Comp: $667.52k
  • Ms. Mina Kim (Age 50)
    CEO & Director
  • Mr. Gilbert M. Labrucherie J.D. (Age 52)
    CFO & Chief Business Officer
  • Mr. Tyler Marciniak
    Head of Investor Relations & Communications
  • Ms. Sanam Pangali J.D.
    Chief Legal Officer & Head of People
  • Dr. Paul M. Peloso M.D. (Age 66)
    M.Sc., Chief Medical Officer
  • Ms. Suzy Buckhalter CPA
    Senior Director of Finance & Accounting
  • Mr. Kenneth A. Lock (Age 50)
    Chief Commercial Officer
  • Dr. Shephard Mpofu M.D.
    Chief Medical Officer
  • Ms. Patricia A. Turney (Age 57)
    Chief Technical Operations Officer

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $7.46 at the beginning of 2024. Since then, SLRN shares have decreased by 23.1% and is now trading at $5.74.
View the best growth stocks for 2024 here
.

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) issued its earnings results on Tuesday, May, 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.93) by $0.57.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering (IPO) on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRN) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners